Actinogen Secures $7.36m R&D Rebate as Alzheimer’s Trial Advances

middle.news 9:44am on Wednesday 11th of February, 2026 AEDT • Healthcare Read Story

Actinogen Secures $7.36m R&D Rebate as Alzheimer’s Trial Advances

9:44am on Wednesday 11th of February, 2026 AEDT Key Points Additional $1.87 million R&D tax rebate from ATO for FY 2025 Total R&D rebate for FY 2025 now $7.36 million Positive Data Monitoring Committee review for Alzheimer’s phase 2b/3 trial Topline trial results expected November 2026 Read Story

middle. Tap to Read Tap the card to read the full analysis about ACW OPEN ARTICLE